Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Recent News
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Nutra Pharma Reports that ReceptoPharm will be Presenting at The Adrenomyeloneuropathy (AMN) Forum in London
February 08, 2005

Nutra Pharma Corp., a biotechnology holding company and incubator that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has today announced that its minority holding, ReceptoPharm, Inc., will make a presentation at the Adrenomyeloneuropathy Forum being held in London on Wednesday, February 9th.

The Adrenomyeloneuropathy Forum is a one-day event being held for physicians, researchers and patients interested in the current state of research for the treatment of AMN and its related symptoms. ReceptoPharm's Chief Executive Officer, Paul F. Reid, PhD, will be presenting to the Forum on the proposed Phase IIb/III study of RPI-78M in AMN.

"Nutra Pharma has agreed to support a Phase IIb/III trial in which the drug will be administered by injection over a fifteen-month trial period. Based on the data received in the previous trial, we believe that efficacy will be demonstrated," comments Rik Deitsch, Nutra Pharma's CEO. "This trial is expected to begin by the end of 2005," he added.

"We are excited at the opportunity to present ReceptoPharm's data and future trial protocol at The Adrenomyeloneuropathy Forum," stated Harold H. Rumph, ReceptoPharm's President. "This is an important step in moving RPI-78M through the clinical process and eventually through regulatory approval," he concluded.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Presenting at the Adrenomyeloneuropathy Forum in London should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy

June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet

June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics